

**Peripheral and Central Nervous System Drugs Advisory Committee Meeting**  
**November 6, 2020**  
**Pre-recorded Presentations**

Both the Food and Drug Administration (FDA) and Biogen, Inc. have prepared pre-recorded presentations for the November 6, 2020, Peripheral and Central Nervous System Drugs Advisory Committee meeting. These pre-recorded presentations will be viewed by the committee prior to the meeting and **will not be replayed on meeting day**.

The recordings of the presentations can be found at the following addresses:

**FDA Presentations (listed in viewing order):**

1. Clinical Overview of Efficacy: Aducanumab for the Treatment of Alzheimer's Disease by Kevin M. Krudys, PhD; Division of Neurology 1 (1 of 3) - <https://collaboration.fda.gov/po1bfo7hfpka>
2. Clinical Overview of Safety: Aducanumab for the Treatment of Alzheimer's Disease by Natalie Branagan, MD and Brian Trummer, MD, PhD ; Division of Neurology 1 (2 of 3) - <https://collaboration.fda.gov/puu0x7miwimi>
3. BLA 761178 Statistical Review: Aducanumab in Alzheimer's by Tristan Massie, PhD; Office of Biostatistics (3 of 3) - <https://collaboration.fda.gov/pradgevcxis7>

**Biogen, Inc. Presentations (listed in viewing order):**

1. Introduction: Aducanumab for the treatment of Alzheimer's Disease by Biogen (1 of 7) - <https://collaboration.fda.gov/py8yfartjef0>
2. Unmet Need: Aducanumab for the treatment of Alzheimer's Disease by Biogen (2 of 7) - <https://collaboration.fda.gov/p3btb1z4k2rl>
3. Clinical Development: Aducanumab for the treatment of Alzheimer's Disease by Biogen (3 of 7) - <https://collaboration.fda.gov/pm67ry34ml2i>
4. Efficacy: Aducanumab for the treatment of Alzheimer's Disease by Biogen (4 of 7) - <https://collaboration.fda.gov/p4w1qpr1rw6y>
5. Study Investigation: Aducanumab for the treatment of Alzheimer's Disease by Biogen (5 of 7) - <https://collaboration.fda.gov/pwb4jutjsndg>
6. Safety: Aducanumab for the treatment of Alzheimer's Disease by Biogen (6 of 7) - <https://collaboration.fda.gov/pf3eij6ty9ws>
7. Clinical Perspective: Aducanumab for the treatment of Alzheimer's Disease by Biogen (7 of 7) - <https://collaboration.fda.gov/pdoqptnl06bb>

Your internet browser may require a plugin to playback these presentations. If your browser does not already have it installed, you may be prompted to download and install it.

The slides and transcripts of these pre-recorded presentations can be found at:  
<https://www.fda.gov/advisory-committees/peripheral-and-central-nervous-system-drugs-advisory-committee/2020-meeting-materials-peripheral-and-central-nervous-system-drugs-advisory-committee>